| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Milk, Human | 28 | 2024 | 94 | 6.490 |
Why?
|
| Breast Neoplasms | 32 | 2024 | 1124 | 4.920 |
Why?
|
| DNA Methylation | 14 | 2021 | 273 | 3.940 |
Why?
|
| Breast Feeding | 8 | 2023 | 138 | 2.070 |
Why?
|
| Biomarkers, Tumor | 9 | 2023 | 454 | 1.810 |
Why?
|
| Lactation | 10 | 2024 | 70 | 1.480 |
Why?
|
| Vegetables | 2 | 2022 | 91 | 1.380 |
Why?
|
| CpG Islands | 8 | 2021 | 212 | 1.300 |
Why?
|
| Receptors, Estrogen | 5 | 2020 | 124 | 1.300 |
Why?
|
| Genes, Tumor Suppressor | 4 | 2014 | 73 | 1.160 |
Why?
|
| Epigenesis, Genetic | 4 | 2020 | 350 | 1.140 |
Why?
|
| Promoter Regions, Genetic | 7 | 2020 | 655 | 1.070 |
Why?
|
| Diet | 4 | 2023 | 635 | 1.000 |
Why?
|
| Leukocytes | 3 | 2021 | 107 | 0.980 |
Why?
|
| Female | 45 | 2024 | 30771 | 0.830 |
Why?
|
| Cytokines | 3 | 2022 | 906 | 0.820 |
Why?
|
| Fruit | 2 | 2022 | 121 | 0.790 |
Why?
|
| Infant | 7 | 2024 | 1527 | 0.750 |
Why?
|
| Antibodies, Neutralizing | 2 | 2024 | 192 | 0.740 |
Why?
|
| Breast | 5 | 2019 | 173 | 0.680 |
Why?
|
| Environmental Exposure | 5 | 2010 | 204 | 0.670 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2023 | 194 | 0.670 |
Why?
|
| Adult | 28 | 2024 | 15711 | 0.630 |
Why?
|
| Humans | 52 | 2024 | 59197 | 0.620 |
Why?
|
| Estradiol | 3 | 2010 | 242 | 0.600 |
Why?
|
| Transforming Growth Factor beta2 | 2 | 2015 | 7 | 0.600 |
Why?
|
| Case-Control Studies | 7 | 2023 | 1056 | 0.570 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 169 | 0.570 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2014 | 59 | 0.550 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 301 | 0.540 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 3 | 2007 | 13 | 0.540 |
Why?
|
| Estrogens | 3 | 2020 | 113 | 0.540 |
Why?
|
| Early Detection of Cancer | 3 | 2024 | 259 | 0.510 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2023 | 135 | 0.480 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2014 | 7 | 0.480 |
Why?
|
| Mass Spectrometry | 3 | 2019 | 285 | 0.480 |
Why?
|
| Neoplasm Invasiveness | 3 | 2014 | 241 | 0.470 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2014 | 29 | 0.470 |
Why?
|
| Biopsy | 2 | 2018 | 373 | 0.470 |
Why?
|
| Spike Glycoprotein, Coronavirus | 3 | 2024 | 97 | 0.460 |
Why?
|
| Estrogen Antagonists | 1 | 2013 | 17 | 0.450 |
Why?
|
| Tamoxifen | 1 | 2013 | 34 | 0.440 |
Why?
|
| DNA, Neoplasm | 2 | 2014 | 51 | 0.440 |
Why?
|
| Water Pollutants, Chemical | 3 | 2017 | 34 | 0.440 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 30 | 0.440 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2013 | 27 | 0.430 |
Why?
|
| Benzhydryl Compounds | 1 | 2014 | 48 | 0.430 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2013 | 28 | 0.430 |
Why?
|
| Pregnancy | 6 | 2023 | 2352 | 0.430 |
Why?
|
| Phenols | 1 | 2014 | 74 | 0.430 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2013 | 58 | 0.420 |
Why?
|
| Endocrine Disruptors | 1 | 2014 | 74 | 0.420 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 179 | 0.410 |
Why?
|
| Proteomics | 5 | 2024 | 252 | 0.400 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2012 | 26 | 0.400 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2020 | 483 | 0.400 |
Why?
|
| Estrogen Receptor alpha | 3 | 2020 | 46 | 0.400 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2012 | 45 | 0.400 |
Why?
|
| Oryzias | 2 | 2010 | 5 | 0.390 |
Why?
|
| Immunoglobulin A | 2 | 2022 | 93 | 0.380 |
Why?
|
| Middle Aged | 14 | 2024 | 16212 | 0.370 |
Why?
|
| Antibodies, Viral | 2 | 2024 | 307 | 0.370 |
Why?
|
| Immunoglobulin G | 2 | 2022 | 450 | 0.350 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 4 | 2018 | 158 | 0.340 |
Why?
|
| Tumor Cells, Cultured | 4 | 2020 | 453 | 0.330 |
Why?
|
| Carcinogens, Environmental | 1 | 2008 | 6 | 0.320 |
Why?
|
| Young Adult | 12 | 2024 | 4315 | 0.300 |
Why?
|
| Biomarkers | 3 | 2022 | 1203 | 0.280 |
Why?
|
| Gene Expression | 3 | 2017 | 807 | 0.280 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2014 | 186 | 0.280 |
Why?
|
| Membrane Proteins | 4 | 2021 | 841 | 0.270 |
Why?
|
| Risk Factors | 7 | 2017 | 4996 | 0.260 |
Why?
|
| Epithelial Cells | 3 | 2014 | 374 | 0.250 |
Why?
|
| Proteome | 3 | 2024 | 135 | 0.240 |
Why?
|
| Thiazines | 1 | 2024 | 1 | 0.240 |
Why?
|
| Vitellogenins | 2 | 2017 | 2 | 0.240 |
Why?
|
| Hazardous Waste | 1 | 2004 | 3 | 0.240 |
Why?
|
| Fuel Oils | 1 | 2004 | 5 | 0.240 |
Why?
|
| Sucrose | 1 | 2024 | 27 | 0.230 |
Why?
|
| Sweetening Agents | 1 | 2024 | 25 | 0.230 |
Why?
|
| Immunization, Secondary | 1 | 2024 | 46 | 0.230 |
Why?
|
| alpha-Mannosidase | 1 | 2004 | 5 | 0.230 |
Why?
|
| Microfluidics | 1 | 2024 | 21 | 0.230 |
Why?
|
| MCF-7 Cells | 2 | 2014 | 65 | 0.220 |
Why?
|
| Saliva | 1 | 2024 | 96 | 0.220 |
Why?
|
| Carbohydrates | 1 | 2004 | 42 | 0.220 |
Why?
|
| Prognosis | 5 | 2020 | 1564 | 0.220 |
Why?
|
| beta-Galactosidase | 1 | 2004 | 81 | 0.220 |
Why?
|
| Glutathione S-Transferase pi | 3 | 2014 | 5 | 0.220 |
Why?
|
| Genes, Reporter | 1 | 2004 | 243 | 0.220 |
Why?
|
| Aged | 6 | 2021 | 13272 | 0.210 |
Why?
|
| Transcriptome | 2 | 2018 | 322 | 0.210 |
Why?
|
| Allergens | 1 | 2023 | 43 | 0.210 |
Why?
|
| Receptors, CCR7 | 1 | 2022 | 6 | 0.210 |
Why?
|
| Cross-Over Studies | 1 | 2023 | 148 | 0.210 |
Why?
|
| Sodium | 1 | 2022 | 59 | 0.210 |
Why?
|
| Immunoglobulin M | 1 | 2022 | 112 | 0.200 |
Why?
|
| Cell Line, Tumor | 4 | 2015 | 1365 | 0.200 |
Why?
|
| Potassium | 1 | 2022 | 109 | 0.200 |
Why?
|
| Colostrum | 1 | 2021 | 4 | 0.190 |
Why?
|
| Immunity, Humoral | 1 | 2021 | 41 | 0.190 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 5060 | 0.190 |
Why?
|
| Leptin | 2 | 2018 | 78 | 0.190 |
Why?
|
| Neoplasm Proteins | 2 | 2013 | 275 | 0.180 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2021 | 62 | 0.180 |
Why?
|
| Endonucleases | 1 | 2021 | 81 | 0.180 |
Why?
|
| Infant, Newborn | 3 | 2022 | 1311 | 0.180 |
Why?
|
| Membrane Transport Proteins | 1 | 2021 | 119 | 0.180 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 176 | 0.180 |
Why?
|
| Mitochondrial Proteins | 1 | 2021 | 99 | 0.180 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2020 | 5 | 0.180 |
Why?
|
| GATA3 Transcription Factor | 1 | 2020 | 15 | 0.180 |
Why?
|
| Prospective Studies | 4 | 2021 | 3093 | 0.170 |
Why?
|
| Age Factors | 3 | 2014 | 1518 | 0.170 |
Why?
|
| Counseling | 1 | 2022 | 351 | 0.170 |
Why?
|
| Vaccination | 1 | 2022 | 336 | 0.170 |
Why?
|
| Electrophoresis | 1 | 2019 | 16 | 0.160 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2021 | 322 | 0.160 |
Why?
|
| Carcinogenesis | 1 | 2020 | 114 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 664 | 0.160 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 374 | 0.160 |
Why?
|
| Limit of Detection | 2 | 2020 | 41 | 0.160 |
Why?
|
| Adiponectin | 1 | 2018 | 34 | 0.160 |
Why?
|
| Transfection | 2 | 2014 | 671 | 0.150 |
Why?
|
| Chromatography, Liquid | 2 | 2020 | 119 | 0.150 |
Why?
|
| Reactive Oxygen Species | 2 | 2010 | 201 | 0.150 |
Why?
|
| Metal Nanoparticles | 2 | 2010 | 179 | 0.150 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 10 | 0.150 |
Why?
|
| Eating | 1 | 2018 | 139 | 0.150 |
Why?
|
| Breast Neoplasms, Male | 1 | 2017 | 14 | 0.150 |
Why?
|
| Genome, Human | 1 | 2019 | 218 | 0.150 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 167 | 0.150 |
Why?
|
| Cytoskeletal Proteins | 2 | 2010 | 194 | 0.140 |
Why?
|
| Nanostructures | 1 | 2020 | 174 | 0.140 |
Why?
|
| Azacitidine | 2 | 2015 | 12 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 387 | 0.140 |
Why?
|
| Weaning | 1 | 2016 | 8 | 0.130 |
Why?
|
| Polymers | 1 | 2020 | 315 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2018 | 520 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 522 | 0.130 |
Why?
|
| Peptides | 1 | 2020 | 548 | 0.130 |
Why?
|
| Specimen Handling | 1 | 2016 | 57 | 0.130 |
Why?
|
| Cohort Studies | 1 | 2022 | 2434 | 0.130 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2012 | 53 | 0.130 |
Why?
|
| Massachusetts | 3 | 2018 | 2083 | 0.130 |
Why?
|
| Phosphorylation | 2 | 2014 | 860 | 0.120 |
Why?
|
| Cyclin D2 | 1 | 2015 | 6 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2018 | 917 | 0.120 |
Why?
|
| DNA-Binding Proteins | 1 | 2021 | 1128 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 3 | 2017 | 498 | 0.120 |
Why?
|
| Melatonin | 1 | 2015 | 66 | 0.120 |
Why?
|
| Radiation Tolerance | 1 | 2015 | 47 | 0.120 |
Why?
|
| Cyclin D1 | 1 | 2014 | 21 | 0.120 |
Why?
|
| Cell Proliferation | 2 | 2020 | 939 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2014 | 18 | 0.120 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 73 | 0.120 |
Why?
|
| Chlamydia trachomatis | 1 | 2014 | 57 | 0.120 |
Why?
|
| Bacterial Adhesion | 1 | 2014 | 59 | 0.120 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2014 | 13 | 0.120 |
Why?
|
| Serine | 1 | 2014 | 83 | 0.120 |
Why?
|
| Protein Isoforms | 1 | 2015 | 193 | 0.120 |
Why?
|
| Solid Phase Extraction | 1 | 2014 | 9 | 0.110 |
Why?
|
| ErbB Receptors | 1 | 2014 | 111 | 0.110 |
Why?
|
| Risk | 1 | 2015 | 370 | 0.110 |
Why?
|
| Proteins | 1 | 2020 | 742 | 0.110 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 696 | 0.110 |
Why?
|
| Adolescent | 5 | 2020 | 5912 | 0.110 |
Why?
|
| Antidepressive Agents | 1 | 2015 | 227 | 0.110 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2014 | 35 | 0.110 |
Why?
|
| Transcriptional Activation | 1 | 2014 | 188 | 0.110 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 2 | 2024 | 35 | 0.110 |
Why?
|
| Mammaplasty | 1 | 2014 | 44 | 0.110 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 2013 | 4 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 37 | 0.110 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2013 | 8 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 1 | 2015 | 153 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2014 | 362 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2013 | 60 | 0.110 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 133 | 0.110 |
Why?
|
| Risk Assessment | 3 | 2018 | 1906 | 0.100 |
Why?
|
| Lipocalins | 1 | 2012 | 4 | 0.100 |
Why?
|
| Lipocalin-2 | 1 | 2012 | 9 | 0.100 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2012 | 17 | 0.100 |
Why?
|
| Chitinase-3-Like Protein 1 | 1 | 2012 | 11 | 0.100 |
Why?
|
| Cell Division | 2 | 2004 | 441 | 0.100 |
Why?
|
| Host-Pathogen Interactions | 1 | 2014 | 238 | 0.100 |
Why?
|
| Adipokines | 1 | 2012 | 28 | 0.100 |
Why?
|
| Acute-Phase Proteins | 1 | 2012 | 34 | 0.100 |
Why?
|
| Cell Cycle | 1 | 2014 | 378 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 291 | 0.100 |
Why?
|
| Breast Diseases | 1 | 2012 | 39 | 0.100 |
Why?
|
| Lectins | 1 | 2012 | 38 | 0.100 |
Why?
|
| Gravidity | 1 | 2012 | 12 | 0.100 |
Why?
|
| Milk Proteins | 1 | 2012 | 45 | 0.100 |
Why?
|
| Primary Prevention | 1 | 2012 | 136 | 0.100 |
Why?
|
| Gold | 2 | 2010 | 226 | 0.100 |
Why?
|
| Repressor Proteins | 1 | 2013 | 336 | 0.090 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2023 | 182 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 453 | 0.090 |
Why?
|
| Cell Movement | 1 | 2013 | 421 | 0.090 |
Why?
|
| RNA Interference | 1 | 2014 | 588 | 0.090 |
Why?
|
| Retinol-Binding Proteins, Cellular | 1 | 2010 | 1 | 0.090 |
Why?
|
| Fishes | 1 | 2010 | 23 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 315 | 0.090 |
Why?
|
| Cations | 1 | 2010 | 63 | 0.090 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2010 | 60 | 0.090 |
Why?
|
| DNA Damage | 2 | 2010 | 275 | 0.090 |
Why?
|
| Cadherins | 1 | 2010 | 67 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 2579 | 0.090 |
Why?
|
| Antigens, CD | 1 | 2010 | 342 | 0.080 |
Why?
|
| Depression | 1 | 2015 | 857 | 0.080 |
Why?
|
| Fluorocarbons | 1 | 2008 | 32 | 0.070 |
Why?
|
| Polybrominated Biphenyls | 1 | 2007 | 3 | 0.070 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2007 | 11 | 0.070 |
Why?
|
| Animals | 7 | 2019 | 19557 | 0.070 |
Why?
|
| Petroleum | 1 | 2007 | 10 | 0.070 |
Why?
|
| Perfume | 1 | 2007 | 1 | 0.070 |
Why?
|
| Polycyclic Compounds | 1 | 2007 | 2 | 0.070 |
Why?
|
| Environmental Pollutants | 1 | 2008 | 90 | 0.070 |
Why?
|
| Male | 6 | 2024 | 27452 | 0.070 |
Why?
|
| Pesticides | 1 | 2007 | 55 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 1 | 2006 | 90 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2010 | 1467 | 0.060 |
Why?
|
| Soil Pollutants | 1 | 2004 | 25 | 0.060 |
Why?
|
| Radiometry | 1 | 2004 | 34 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2014 | 2884 | 0.060 |
Why?
|
| Heat-Shock Proteins | 1 | 2004 | 66 | 0.060 |
Why?
|
| Response Elements | 1 | 2004 | 42 | 0.060 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2004 | 16 | 0.060 |
Why?
|
| Plant Lectins | 1 | 2004 | 6 | 0.060 |
Why?
|
| Acetylglucosamine | 1 | 2004 | 11 | 0.060 |
Why?
|
| Binding, Competitive | 1 | 2004 | 102 | 0.060 |
Why?
|
| Galactose | 1 | 2004 | 12 | 0.060 |
Why?
|
| Lactose | 1 | 2004 | 13 | 0.060 |
Why?
|
| Antibody Formation | 1 | 2024 | 111 | 0.060 |
Why?
|
| Carbohydrate Metabolism | 1 | 2004 | 48 | 0.060 |
Why?
|
| Postpartum Period | 2 | 2018 | 203 | 0.060 |
Why?
|
| Cell Separation | 1 | 2024 | 147 | 0.060 |
Why?
|
| Quality Control | 2 | 2017 | 70 | 0.050 |
Why?
|
| Plant Proteins | 1 | 2004 | 83 | 0.050 |
Why?
|
| Time Factors | 1 | 2010 | 3562 | 0.050 |
Why?
|
| Fluorescent Dyes | 1 | 2004 | 195 | 0.050 |
Why?
|
| Xenobiotics | 1 | 2002 | 12 | 0.050 |
Why?
|
| Endocrine System | 1 | 2002 | 18 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 692 | 0.050 |
Why?
|
| Mothers | 1 | 2024 | 261 | 0.050 |
Why?
|
| HeLa Cells | 2 | 2014 | 527 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 438 | 0.050 |
Why?
|
| Public Health | 1 | 2002 | 180 | 0.040 |
Why?
|
| DNA | 1 | 2024 | 787 | 0.040 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2020 | 91 | 0.040 |
Why?
|
| Fas Ligand Protein | 1 | 2018 | 39 | 0.040 |
Why?
|
| Fibroblast Growth Factors | 1 | 2018 | 63 | 0.040 |
Why?
|
| Cyprinidae | 1 | 2017 | 4 | 0.040 |
Why?
|
| Ethinyl Estradiol | 1 | 2017 | 9 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 263 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2020 | 1580 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 132 | 0.030 |
Why?
|
| Turkey | 1 | 2014 | 13 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2014 | 96 | 0.030 |
Why?
|
| Apoptosis | 1 | 2020 | 1034 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 253 | 0.030 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2014 | 17 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 450 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 436 | 0.030 |
Why?
|
| Software | 1 | 2017 | 365 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2017 | 326 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2014 | 255 | 0.030 |
Why?
|
| United States | 3 | 2015 | 7484 | 0.030 |
Why?
|
| Oxidative Stress | 2 | 2007 | 280 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 1545 | 0.030 |
Why?
|
| Women's Health | 1 | 2015 | 390 | 0.030 |
Why?
|
| Parity | 1 | 2012 | 71 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2012 | 71 | 0.030 |
Why?
|
| Kallikreins | 1 | 2012 | 9 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 106 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 542 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2012 | 2056 | 0.020 |
Why?
|
| Comet Assay | 1 | 2010 | 11 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 675 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 456 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 2323 | 0.020 |
Why?
|
| Biological Transport | 1 | 2010 | 287 | 0.020 |
Why?
|
| Surface Properties | 1 | 2010 | 270 | 0.020 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2010 | 248 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2010 | 257 | 0.020 |
Why?
|
| Cell Survival | 1 | 2010 | 549 | 0.020 |
Why?
|
| Maternal Exposure | 1 | 2008 | 40 | 0.020 |
Why?
|
| United States Environmental Protection Agency | 1 | 2007 | 6 | 0.020 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2007 | 35 | 0.020 |
Why?
|
| Xylenes | 1 | 2007 | 5 | 0.020 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2007 | 2 | 0.020 |
Why?
|
| Benzopyrans | 1 | 2007 | 7 | 0.020 |
Why?
|
| Environmental Monitoring | 1 | 2008 | 139 | 0.020 |
Why?
|
| Neoplasms | 2 | 2010 | 1226 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 1534 | 0.020 |
Why?
|
| Metals, Heavy | 1 | 2002 | 8 | 0.010 |
Why?
|
| Organic Chemicals | 1 | 2002 | 18 | 0.010 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2002 | 32 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2002 | 115 | 0.010 |
Why?
|
| Infertility, Male | 1 | 2002 | 58 | 0.010 |
Why?
|
| Mice | 1 | 2014 | 10235 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2002 | 95 | 0.010 |
Why?
|
| Spermatozoa | 1 | 2002 | 252 | 0.010 |
Why?
|
| Disease Progression | 1 | 2002 | 1038 | 0.010 |
Why?
|